Browsing by Author "Dikici D.S."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Quickly diagnosed and treated prepubertal Type 1 narcolepsy case
    (Taylor and Francis Ltd., 2018) Çökmüş F.P.; Aydın O.; Dikici D.S.; Sapmaz Ş.Y.
    Excessive daytime sleepiness, cataplexy, sleep paralysis, and hypnagogic hallucination are the classic tetrad of narcolepsy. It has been shown that narcolepsy, a chronic and disabling disease, starts in childhood and adolescence rather than adulthood. The International Classification of Sleep Disorder (ICSD-3) classifies narcolepsy into Type 1 (narcolepsy with cataplexy) and Type 2 (narcolepsy without cataplexy). There is low awareness and knowledge of narcolepsy among the general public, primary care physicians, and sleep specialists. It has been shown that the lack of recognition of disease symptoms delayed the diagnosis of narcolepsy from 8.7 to 22.1 years. In this case report, we will discuss the case of Type 1 narcolepsy, which started in the prepubertal period and was diagnosed and treated in a short period of time. © 2017 The Author(s).
  • No Thumbnail Available
    Item
    DSM-5 ayrılma anksiyetesi bozukluğu şiddet ölçeği-erişkin formunun geçerliliği ve güvenilirliği
    (Yerkure Tanitim ve Yayincilik, 2020) Çöldür E.Ö.; Çökmüş F.P.; Dikici D.S.; Aydemir Ö.
    [No abstract available]
  • No Thumbnail Available
    Item
    Evaluation of Emotional Adverse Effects of Antidepressants: A Follow-up Study
    (Lippincott Williams and Wilkins, 2020) Asçibasi K.; Çökmüs F.P.; Dikici D.S.; Özkan H.M.; Alçi D.; Altunsoy N.; Kuru E.; Yüzeren S.; Aydemir Ö.
    Purpose/Background Emotional adverse effects due to antidepressant use may cause difficulties for the clinician in the treatment of depression. In this prospective study, the emotional adverse effects of antidepressants were evaluated in various aspects. Methods/Procedures Ninety eight patients diagnosed with major depressive disorder were included in the study. At 2nd, 4th, 8th, 12th, and 16th weeks, patients were assessed with Montgomery-Asberg Depression Rating Scale (MADRS), and the antidepressant dose was increased in patients with less than a 50% reduction at each visit compared with the initial MADRS score. The Oxford Questionnaire on the Emotional Side-effects of Antidepressants (OQESA) was used at the 8th-week and 16th-week visits. Findings/Results A significant difference is found in the OQESA score at the 8th-week visit compared with the 16th-week assessment (P < 0.001, t = 5.73). There were significant correlations between MADRS scores and OQESA scores both at the 8th (r = 0.346, P = 0.05) and the 16th (r = 0.490, P < 0.001) weeks. In regression analyses, at eighth-week assessment, MADRS score (B = 1.487, P = 0.002) and selective serotonin reuptake inhibitor use (B = 14.014, P = 0.023) had a significantly predicted OQESA score. Implications/Conclusions In this study, it is found that, as the rate of remitted patients is increased, OQESA scores get decreased, and furthermore, the OQESA score of the remitted group is statistically low when compared with that of the nonremitted group at the 8th- and 16th-week visits. Oxford Questionnaire on the Emotional Side-effects of Antidepressants and MADRS scores are significantly correlated in all assessments. These results suggest that the score obtained from OQESA may be related not only to the emotional adverse effects of antidepressants but also to the residual symptoms of depression. © Wolters Kluwer Health, Inc. All rights reserved.